JP5090423B2 - モルホリノプリン誘導体 - Google Patents
モルホリノプリン誘導体 Download PDFInfo
- Publication number
- JP5090423B2 JP5090423B2 JP2009236444A JP2009236444A JP5090423B2 JP 5090423 B2 JP5090423 B2 JP 5090423B2 JP 2009236444 A JP2009236444 A JP 2009236444A JP 2009236444 A JP2009236444 A JP 2009236444A JP 5090423 B2 JP5090423 B2 JP 5090423B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituents selected
- alkylamino
- mmol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YJGPBDTYCWJGEX-UHFFFAOYSA-N CC(C)(C)OC(N(C)c(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl)=O Chemical compound CC(C)(C)OC(N(C)c(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl)=O YJGPBDTYCWJGEX-UHFFFAOYSA-N 0.000 description 1
- VQLYVJDDZMXVAF-UHFFFAOYSA-N CC(C)(C)OC(N(C)c(nc1)ncc1-c1nc(N2CCOCC2)c2nc[n](CC3COCC3)c2n1)=O Chemical compound CC(C)(C)OC(N(C)c(nc1)ncc1-c1nc(N2CCOCC2)c2nc[n](CC3COCC3)c2n1)=O VQLYVJDDZMXVAF-UHFFFAOYSA-N 0.000 description 1
- WSHLFIJGHOVUFO-FQVRHNBASA-N CC(C)(C)OC(N(C)c(nc1)ncc1C1=N[C@H]2N(CC3COCC3)C(C)=NC2C(N2CCOCC2)=N1)=O Chemical compound CC(C)(C)OC(N(C)c(nc1)ncc1C1=N[C@H]2N(CC3COCC3)C(C)=NC2C(N2CCOCC2)=N1)=O WSHLFIJGHOVUFO-FQVRHNBASA-N 0.000 description 1
- XNRIKJPJINSPRL-UHFFFAOYSA-N CNc(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl Chemical compound CNc(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl XNRIKJPJINSPRL-UHFFFAOYSA-N 0.000 description 1
- JEVGFJHCXRAHLJ-UHFFFAOYSA-N CS(N(CC1)CCN1c1nc2c(N3CCOCC3)nc(-c(cc3)cnc3N)nc2[n]1CC1COCC1)(=O)=O Chemical compound CS(N(CC1)CCN1c1nc2c(N3CCOCC3)nc(-c(cc3)cnc3N)nc2[n]1CC1COCC1)(=O)=O JEVGFJHCXRAHLJ-UHFFFAOYSA-N 0.000 description 1
- ZZAKLGGGMWORRT-UHFFFAOYSA-N CS(N1CCNCC1)(=O)=O Chemical compound CS(N1CCNCC1)(=O)=O ZZAKLGGGMWORRT-UHFFFAOYSA-N 0.000 description 1
- IZDYYCLYTQYTHQ-AWEZNQCLSA-N C[C@@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O Chemical compound C[C@@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O IZDYYCLYTQYTHQ-AWEZNQCLSA-N 0.000 description 1
- IZDYYCLYTQYTHQ-CQSZACIVSA-N C[C@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O Chemical compound C[C@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O IZDYYCLYTQYTHQ-CQSZACIVSA-N 0.000 description 1
- MFJDBCRDNQDMTF-UHFFFAOYSA-N Cc(nc(N)nc1)c1-c(nc1[n]2CC3CC3)nc(N3CCOCC3)c1nc2N(CC1)CCN1S=O Chemical compound Cc(nc(N)nc1)c1-c(nc1[n]2CC3CC3)nc(N3CCOCC3)c1nc2N(CC1)CCN1S=O MFJDBCRDNQDMTF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009236444A JP5090423B2 (ja) | 2008-10-14 | 2009-10-13 | モルホリノプリン誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008264797 | 2008-10-14 | ||
| JP2008264797 | 2008-10-14 | ||
| JP2009121690 | 2009-05-20 | ||
| JP2009121690 | 2009-05-20 | ||
| JP2009236444A JP5090423B2 (ja) | 2008-10-14 | 2009-10-13 | モルホリノプリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011001339A JP2011001339A (ja) | 2011-01-06 |
| JP2011001339A5 JP2011001339A5 (enExample) | 2012-09-20 |
| JP5090423B2 true JP5090423B2 (ja) | 2012-12-05 |
Family
ID=42106564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009236444A Expired - Fee Related JP5090423B2 (ja) | 2008-10-14 | 2009-10-13 | モルホリノプリン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8097622B2 (enExample) |
| EP (1) | EP2336132B1 (enExample) |
| JP (1) | JP5090423B2 (enExample) |
| KR (1) | KR101614976B1 (enExample) |
| CN (1) | CN102245607B (enExample) |
| AU (1) | AU2009304789B2 (enExample) |
| BR (1) | BRPI0920199A2 (enExample) |
| CA (1) | CA2740471C (enExample) |
| CO (1) | CO6362009A2 (enExample) |
| DK (1) | DK2336132T3 (enExample) |
| ES (1) | ES2452541T3 (enExample) |
| IL (1) | IL212278A (enExample) |
| MX (1) | MX2011003490A (enExample) |
| MY (1) | MY156456A (enExample) |
| NZ (1) | NZ592761A (enExample) |
| PL (1) | PL2336132T3 (enExample) |
| PT (1) | PT2336132E (enExample) |
| RU (1) | RU2490269C2 (enExample) |
| TW (1) | TWI378933B (enExample) |
| WO (1) | WO2010044401A1 (enExample) |
| ZA (1) | ZA201102449B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2279188B1 (en) * | 2008-05-30 | 2015-01-28 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CN102711766B (zh) * | 2009-11-12 | 2014-06-04 | 霍夫曼-拉罗奇有限公司 | N-9-取代的嘌呤化合物、组合物和使用方法 |
| CN102260263A (zh) * | 2010-05-26 | 2011-11-30 | 四川大学 | 一类二苯胺基嘌呤衍生物及制备方法和医药用途 |
| KR101531117B1 (ko) | 2010-07-14 | 2015-06-23 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대해 선택적인 퓨린 화합물, 및 사용 방법 |
| BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
| KR20140090218A (ko) | 2011-10-28 | 2014-07-16 | 노파르티스 아게 | 신규 퓨린 유도체 및 질환의 치료에서의 그의 용도 |
| CN103012284A (zh) * | 2012-12-26 | 2013-04-03 | 无锡捷化医药科技有限公司 | 一种2-氨基-5-溴嘧啶类化合物的制备方法 |
| WO2014185368A1 (ja) * | 2013-05-13 | 2014-11-20 | 第一三共株式会社 | ５－｛８－［（３ｒ）－４－アセチル－３－メチルピペラジン－１－イル］－６－モルホリン－４－イル－９－（２，２，２－トリフルオロエチル）－９ｈ－プリン－２－イル｝ピリミジン－２－アミン、およびその薬理上許容される塩の新規な結晶、およびその製造方法 |
| TW201520215A (zh) * | 2013-05-13 | 2015-06-01 | Daiichi Sankyo Co Ltd | Ｎ－□啉基嘌呤衍生物之製造方法 |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| ES2721302T3 (es) * | 2013-10-04 | 2019-07-30 | Univ Basel | Inhibidores de PI3k y mTOR conformacionalmente restringidos |
| AU2016242080B2 (en) | 2015-03-30 | 2019-09-19 | Daiichi Sankyo Company, Limited | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors |
| CN108602825A (zh) * | 2016-02-05 | 2018-09-28 | 中央研究院 | 具有抗癌活性的嘌呤化合物 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| ES2911522T3 (es) | 2016-12-02 | 2022-05-19 | Daiichi Sankyo Co Ltd | Novedosa endo-ß-n-acetilglucosaminidasa |
| EP3360865A1 (en) | 2017-02-13 | 2018-08-15 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272 |
| TWI837231B (zh) | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 |
| CN113368114B (zh) * | 2020-03-10 | 2022-04-22 | 四川大学 | 一种吗啉嘧啶类化合物的抗肿瘤应用 |
| BR112023018799A2 (pt) * | 2021-03-17 | 2023-12-12 | Medivir Ab | Derivados de purina como agentes anticâncer |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864145A (en) * | 1959-06-02 | 1961-03-29 | Thomae Gmbh Dr K | Novel purines and a process for their manufacture |
| WO2001083456A1 (en) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP3810017B2 (ja) | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| PT1389617E (pt) | 2001-04-27 | 2007-04-30 | Zenyaku Kogyo Kk | Composto heterocíclico e agente antitumoral contendo o mesmo como igrediente activo |
| US7122665B2 (en) | 2002-10-15 | 2006-10-17 | Synta Pharmaceuticals Corp. | Heterocyclic compounds |
| AU2003275630B2 (en) | 2002-10-25 | 2010-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agent comprising the same as effective component |
| WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| AU2005249380C1 (en) * | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| NZ594628A (en) | 2005-10-07 | 2013-04-26 | Exelixis Inc | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka |
| CN102746298A (zh) | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007127175A2 (en) | 2006-04-26 | 2007-11-08 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| TW200801012A (en) | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| CA2650196A1 (en) | 2006-04-26 | 2007-11-01 | Stewart James Baker | Pyrimidine derivatives as pi3k inhibitors |
| GB0611152D0 (en) | 2006-06-06 | 2006-07-19 | Ucb Sa | Therapeutic agents |
| ES2657635T3 (es) | 2006-08-08 | 2018-03-06 | Chugai Seiyaku Kabushiki Kaisha | Derivado de pirimidina como inhibidor de PI3K y uso del mismo |
| HUE033894T2 (en) | 2006-08-23 | 2018-01-29 | Kudos Pharm Ltd | 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors |
| EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008032028A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032072A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| US20090325954A1 (en) | 2006-09-14 | 2009-12-31 | Sam Butterworth | 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| GB0620818D0 (en) | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
| MX2009004077A (es) | 2006-10-19 | 2009-05-05 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| JP2010510245A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス化合物 |
| EP2114950B1 (en) | 2006-12-07 | 2016-03-09 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| AU2007329352B2 (en) | 2006-12-07 | 2013-01-17 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US8173647B2 (en) | 2007-02-06 | 2012-05-08 | Gordana Atallah | PI 3-kinase inhibitors and methods of their use |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| US20080233127A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| KR20100016433A (ko) | 2007-04-12 | 2010-02-12 | 에프. 호프만-라 로슈 아게 | 포스파티딜이노시톨-3-키나제의 저해제로서의 피리미딘 유도체 |
| GB0707087D0 (en) | 2007-04-12 | 2007-05-23 | Piramed Ltd | Pharmaceutical compounds |
| EP2146981A1 (en) | 2007-04-12 | 2010-01-27 | F. Hoffmann-Roche AG | Pharmaceutical compounds |
| WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
| US7893060B2 (en) | 2007-06-12 | 2011-02-22 | F. Hoffmann-La Roche Ag | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
| EA201000092A1 (ru) | 2007-07-09 | 2010-06-30 | Астразенека Аб | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| ES2399774T3 (es) | 2007-09-24 | 2013-04-03 | Genentech, Inc. | Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso |
| KR20160116045A (ko) | 2007-10-05 | 2016-10-06 | 베라스템, 인코포레이티드 | 피리미딘 치환된 퓨린 유도체 |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| JP5547637B2 (ja) | 2007-10-05 | 2014-07-16 | インデックス・ファーマシューティカルズ・アクチエボラーグ | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
| JP2011500702A (ja) | 2007-10-16 | 2011-01-06 | ワイス・エルエルシー | チエノピリミジンおよびピラゾロピリミジン化合物ならびにｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのその使用 |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| WO2009053716A1 (en) | 2007-10-26 | 2009-04-30 | F.Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
| GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| US20090149458A1 (en) | 2007-11-27 | 2009-06-11 | Wyeth | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
| GB0723747D0 (en) | 2007-12-04 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
| GB0723748D0 (en) | 2007-12-04 | 2008-01-16 | Ucb Pharma Sa | Therapeutic agents |
| WO2009071895A1 (en) | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Fused thiazole and thiophene derivatives as kinase inhibitors |
| WO2009071890A1 (en) | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Tricyclic kinase inhibitors |
| US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| EA201001017A1 (ru) | 2008-01-15 | 2011-02-28 | ВАЙЕТ ЭлЭлСи | 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы |
| WO2009093981A1 (en) | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
| EP2231152B1 (en) | 2008-01-24 | 2014-01-01 | SignalRX Pharmaceuticals, Inc. | Thienopyranones as kinase inhibitors |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| JP2011510071A (ja) | 2008-01-25 | 2011-03-31 | アストラゼネカ アクチボラグ | 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６ |
| CL2009000241A1 (es) | 2008-02-07 | 2010-09-03 | Chugai Pharmaceutical Co Ltd | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. |
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
-
2009
- 2009-10-12 TW TW098134442A patent/TWI378933B/zh not_active IP Right Cessation
- 2009-10-13 PT PT98205792T patent/PT2336132E/pt unknown
- 2009-10-13 MX MX2011003490A patent/MX2011003490A/es active IP Right Grant
- 2009-10-13 WO PCT/JP2009/067738 patent/WO2010044401A1/ja not_active Ceased
- 2009-10-13 NZ NZ592761A patent/NZ592761A/en not_active IP Right Cessation
- 2009-10-13 KR KR1020117008413A patent/KR101614976B1/ko not_active Expired - Fee Related
- 2009-10-13 ES ES09820579.2T patent/ES2452541T3/es active Active
- 2009-10-13 CA CA2740471A patent/CA2740471C/en not_active Expired - Fee Related
- 2009-10-13 JP JP2009236444A patent/JP5090423B2/ja not_active Expired - Fee Related
- 2009-10-13 CN CN200980151585.4A patent/CN102245607B/zh not_active Expired - Fee Related
- 2009-10-13 DK DK09820579.2T patent/DK2336132T3/da active
- 2009-10-13 MY MYPI2011001420A patent/MY156456A/en unknown
- 2009-10-13 BR BRPI0920199A patent/BRPI0920199A2/pt not_active IP Right Cessation
- 2009-10-13 AU AU2009304789A patent/AU2009304789B2/en not_active Ceased
- 2009-10-13 PL PL09820579T patent/PL2336132T3/pl unknown
- 2009-10-13 RU RU2011119525/04A patent/RU2490269C2/ru not_active IP Right Cessation
- 2009-10-13 EP EP09820579.2A patent/EP2336132B1/en not_active Not-in-force
- 2009-10-14 US US12/579,175 patent/US8097622B2/en not_active Expired - Fee Related
-
2011
- 2011-04-01 ZA ZA2011/02449A patent/ZA201102449B/en unknown
- 2011-04-12 IL IL212278A patent/IL212278A/en not_active IP Right Cessation
- 2011-05-09 CO CO11056552A patent/CO6362009A2/es active IP Right Grant
- 2011-11-30 US US13/308,239 patent/US8309546B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5090423B2 (ja) | モルホリノプリン誘導体 | |
| EP3529241B1 (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| EP3733663B1 (en) | 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer | |
| TW202334138A (zh) | 癌症治療方法 | |
| EP4549439A1 (en) | Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof | |
| SG185617A1 (en) | Purinone derivative | |
| EP2483272A2 (en) | Pi3k (delta) selective inhibitors | |
| WO2010005558A2 (en) | Pi3k isoform selective inhibitors | |
| TW202204365A (zh) | 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合 | |
| EP2571884A2 (en) | Mtor selective kinase inhibitors | |
| JP2022529152A (ja) | Ｃｄ７３阻害剤 | |
| JP2011236198A (ja) | モルホリノプリン誘導体 | |
| EP3546458A1 (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| EP2065388B1 (en) | Pyrazolopyrimidine derivative | |
| JP5565913B2 (ja) | 三環性ピラゾロピリミジン誘導体 | |
| RS59213B1 (sr) | 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primena kao pi3k inhibitora | |
| JP2025519493A (ja) | Ｄｇｋ阻害剤としての三環式トリアゾロ化合物 | |
| HK1158189B (en) | Morpholinopurine derivative | |
| JP2012067087A (ja) | 三環性ピラゾロピリミジン誘導体 | |
| HK40040029A (en) | 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer | |
| HK1164308A (en) | Tricyclic pyrazolopyrimidine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120807 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20120807 |
|
| TRDD | Decision of grant or rejection written | ||
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20120829 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120903 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120912 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150921 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5090423 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |